Male patients with evidence of mHSPC at any point during the study period.
At least one dispensing of darolutamide or enzalutamide or apalutamide or abiraterone acetate/methylprednisolone, initiated for the first time during the patient identification period for mHSPC
Age ≥18 years at index date.
At least 12 months of data prior to index date (a sensitivity analysis will also be conducted using 6 months pre-index period)
At least 3 months of data after index date (a sensitivity analysis will also be conducted using 6 months post-index period)
You may not be if
Evidence of prior use of ARPI, including darolutamide, enzalutamide, apalutamide, or abiraterone/methylprednisolone, before the index date
Evidence of castration resistant prostate cancer (CRPC), either metastatic or nonmetastatic, before or on the index date, proxied by timing of medications in use.
